Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Horizon Therapeutics plc
Headquarters:
Dublin, Ireland
Website:
N/A
Year Founded:
2008
Status:
Acquired
BioCentury
|
Apr 25, 2025
Data Byte
CHMP recommends six orphan medicines
Seven new products get positive opinions in April
Read More
BioCentury
|
Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
Read More
BioCentury
|
Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
Read More
BioCentury
|
Jan 30, 2025
Management Tracks
Wyman joins Scholar Rock
Plus: Danilkowicz to lead commercial at Alumis and an update from Precision
Read More
BioCentury
|
Dec 5, 2024
Finance
Broadening Versant’s obesity portfolio, Antag plots clinical path with €80M
Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more
Read More
BioCentury
|
Aug 24, 2024
Deals
Pharma deals pivot from high-risk modalities, targets
BioCentury’s analysis of 12 months of dealmaking between biotechs and top pharmas
Read More
BioCentury
|
May 9, 2024
Management Tracks
C-suite changes at Acelyrin could signal reprioritizations in pipeline
With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way
Read More
BioCentury
|
Apr 4, 2024
Management Tracks
Upstream names new CEO, CFO and COO
Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more
Read More
BioCentury
|
Mar 26, 2024
Management Tracks
Former BioMarin CEO Bienaimé named chair of Owkin
Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney
Read More
BioCentury
|
Feb 23, 2024
Product Development
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals
The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients
Read More
Items per page:
10
1 - 10 of 107
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help